Cassava Sciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.
Cassava Sciences reports discontinuation of Alzheimer's clinical trials, a settlement with the SEC, and a strategic shift towards Tuberous Sclerosis Complex (TSC)-related epilepsy in its 2024 10-K filing.
Cassava Sciences outlines its common stock and warrant details, including authorized shares, voting rights, and warrant exercise conditions, in its annual 10-K filing.